Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.

We have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.

G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Type
Public
HQ
King of Prussia, US
Founded
2008
Employees
53 (est)+13%
Trevena was founded in 2008 and is headquartered in King of Prussia, US

Trevena Locations

King of Prussia, US

Trevena Metrics

Trevena Summary

Market capitalization

$289 M

Closing share price

$5.62
Trevena's latest market capitalization is $289 M.

Trevena Market Value History

Trevena News

Trevena Company Life

You may also be interested in